Journal of Liver Cancer最新文献_第9页

Rare Clinical and Radiologic Case of Cholangiocarcinoma Mimicking Pyogenic Abscess, Hepatic Echinococcal Cysts, and Metastases. 胆管癌模拟化脓性脓肿、肝包虫病囊肿及转移的罕见临床及影像学病例。

Journal of Liver Cancer Pub Date : 2020-09-01 DOI: 10.17998/jlc.20.2.173

Si Hyeong Lee, Soo Hyung Ryu, Dong Hoon Lee, Won Eui Yoon, Tae Young Park, Hye Kyung Lee, Jeong Seop Moon

引用次数: 0

Validation of the Korean Liver Cancer Association-National Cancer Center 2018 Criteria for the Noninvasive Diagnosis of Hepatocellular Carcinoma Using Magnetic Resonance Imaging. 韩国肝癌协会-国家癌症中心2018年肝细胞癌磁共振成像无创诊断标准的验证。

Journal of Liver Cancer Pub Date : 2020-09-01 DOI: 10.17998/jlc.20.2.120

Sunyoung Lee, Myeong-Jin Kim

{"title":"Validation of the Korean Liver Cancer Association-National Cancer Center 2018 Criteria for the Noninvasive Diagnosis of Hepatocellular Carcinoma Using Magnetic Resonance Imaging.","authors":"Sunyoung Lee, Myeong-Jin Kim","doi":"10.17998/jlc.20.2.120","DOIUrl":"https://doi.org/10.17998/jlc.20.2.120","url":null,"abstract":"Background/aims: This study aimed to assess the validity and diagnostic performance of the imaging criteria of Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) 2018 using magnetic resonance imaging (MRI) in high-risk patients for HCC.Methods: This retrospective study included 142 treatment-naïve patients (81 patients who underwent MRI with extracellular contrast agent and 61 who underwent MRI with hepatobiliary agent; 183 lesions including 149 HCCs) with a high risk of HCC who underwent multiphasic contrast-enhanced MRI from January to December 2015. All lesions were categorized according to the KLCA-NCC 2018 imaging diagnostic criteria by two readers, and per-lesion diagnostic performances were compared.Results: According to the KLCA-NCC 2018, none (0%) of the 13 benign category lesions, 11 (44.0%) of 25 indeterminate category lesions, 15 (93.8%) of 16 probable HCC category lesions, and 97 (99.0%) of 98 definite HCC category lesions were ultimately diagnosed as HCCs. The sensitivity and specificity of definite HCC category were 65.1% and 97.1%, respectively, and those of the combination of definite and probable HCC categories were 75.2% and 94.1%, respectively. The sensitivity of the combination of definite and probable HCC categories was significantly higher than that of definite HCC (P<0.001), but the specificity was not significantly lower (P>0.999).Conclusions: The noninvasive imaging diagnosis of KLCA-NCC 2018 on MRI is reliable and useful for diagnosing HCC in high-risk patients. Combining definite and probable HCC categories of KLCA-NCC 2018 improves the sensitivity while maintaining a high specificity.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"20 2","pages":"120-127"},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/57/9d/jlc-20-2-120.PMC10035670.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9734950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Long-term Survival of a Patient with a Large Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis and Spontaneous Tumor Rupture. 大肝癌合并门静脉肿瘤血栓形成及自发性肿瘤破裂患者的长期生存分析。

Journal of Liver Cancer Pub Date : 2020-09-01 DOI: 10.17998/jlc.20.2.148

Hyung-Woo Lee, Gi-Ae Kim, Chi Hyuk Oh, Jae-Jun Shim, Byung-Ho Kim

引用次数: 0

Infiltration of T Cells and Programmed Cell Death Ligand 1-expressing Macrophages as a Potential Predictor of Lenvatinib Response in Hepatocellular Carcinoma. T细胞浸润和表达程序细胞死亡配体1的巨噬细胞作为肝细胞癌Lenvatinib反应的潜在预测因子

Journal of Liver Cancer Pub Date : 2020-09-01 DOI: 10.17998/jlc.20.2.128

Pil Soo Sung, Sung Woo Cho, Jaejun Lee, Hyun Yang, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon

{"title":"Infiltration of T Cells and Programmed Cell Death Ligand 1-expressing Macrophages as a Potential Predictor of Lenvatinib Response in Hepatocellular Carcinoma.","authors":"Pil Soo Sung, Sung Woo Cho, Jaejun Lee, Hyun Yang, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon","doi":"10.17998/jlc.20.2.128","DOIUrl":"https://doi.org/10.17998/jlc.20.2.128","url":null,"abstract":"Background/Aims Lenvatinib was recently proven to be non-inferior to sorafenib in treating unresectable hepatocellular carcinoma (HCC) in a phase-3 randomized controlled trial. In this study, we investigated whether the response to lenvatinib was affected by tumor immunogenicity. Methods Between May 2019 and April 2020, nine patients with intermediate-to-advanced HCC, who were treated with lenvatinib after liver biopsy, were enrolled. Immunohistochemical staining and multi-color flow cytometry were performed on specimens obtained from liver biopsy. Results Among the nine patients enrolled, four showed objective responses (complete responses+partial responses). Immunohistochemical staining for CD3, CD68, and programmed cell death ligand 1 (PD-L1) demonstrated that patients with objective responses showed marked infiltration of T cells and PD-L1-expressing macrophages in intra-tumoral and peri-tumoral tissues compared to those without objective responses. A significant difference in the numbers of infiltrated T cells, both in the intra-tumoral (P<0.01) and peri-tumoral regions (P<0.05), were identified between responders and non-responders. Regarding the number of infiltrated macrophages, no significant difference was found between the responders and non-responders, although the number of PD-L1-expressing tumor-associated macrophages was significantly higher in responders than that in non-responders (P<0.05). Conclusions Tumor immunogenicity, as indicated by T cell and PD-L1-positive macrophage infiltration, affects lenvatinib response in unresectable HCC.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"20 2","pages":"128-134"},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f3/ad/jlc-20-2-128.PMC10035673.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9728087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Early Experience of Oncolytic Virus Injection Combined with Sorafenib in a Patient with Advanced Hepatocellular Carcinoma and Portal Vein Thrombosis. 溶瘤病毒注射液联合索拉非尼治疗晚期肝癌合并门静脉血栓的早期体会。

Journal of Liver Cancer Pub Date : 2020-09-01 DOI: 10.17998/jlc.20.2.177

Hyun Ho Jo, Seong Joon Chun, Jeong-Ju Yoo, Min Hee Lee, Sang Gyune Kim, Young Seok Kim

引用次数: 0

Imaging Modalities for Hepatocellular Carcinoma Surveillance: Expanding Horizons beyond Ultrasound. 肝细胞癌监测的影像学模式:超越超声的视野。

Journal of Liver Cancer Pub Date : 2020-09-01 DOI: 10.17998/jlc.20.2.99

Hyo Jung Park, So Yeon Kim

引用次数: 1

Hepatocellular Carcinoma in Korea between 2012 and 2014: an Analysis of Data from the Korean Nationwide Cancer Registry. 2012年至2014年间韩国的肝细胞癌：韩国全国癌症登记数据分析》（Hepatocellular Carcinoma in Korea between 2012 and 2014: an Analysis of Data from Korean Nationalwide Cancer Registry）。

Journal of Liver Cancer Pub Date : 2020-09-01 Epub Date: 2020-09-30 DOI: 10.17998/jlc.20.2.135

Young Eun Chon, Han Ah Lee, Jun Sik Yoon, Jun Yong Park, Bo Hyun Kim, In Joon Lee, Suk Kyun Hong, Dong Hyeon Lee, Hyun-Joo Kong, Eunyang Kim, Young-Joo Won, Jeong-Hoon Lee

{"title":"Hepatocellular Carcinoma in Korea between 2012 and 2014: an Analysis of Data from the Korean Nationwide Cancer Registry.","authors":"Young Eun Chon, Han Ah Lee, Jun Sik Yoon, Jun Yong Park, Bo Hyun Kim, In Joon Lee, Suk Kyun Hong, Dong Hyeon Lee, Hyun-Joo Kong, Eunyang Kim, Young-Joo Won, Jeong-Hoon Lee","doi":"10.17998/jlc.20.2.135","DOIUrl":"10.17998/jlc.20.2.135","url":null,"abstract":"Background/aims: Considering the high prevalence and mortality of hepatocellular carcinoma (HCC) in Korea, accurate statistics for HCC are important. We evaluated the characteristics of Korean patients with newly diagnosed HCC.Methods: We retrospectively evaluated data from the Korean Primary Liver Cancer Registry (KPLCR). The baseline characteristics, treatment modalities, and overall survival (OS) of 4,572 patients with HCC registered in the KPLCR between 2012 and 2014 were investigated.Results: At the time of HCC diagnosis, the median age was 60.0 years, with male predominance (79.6%). Hepatitis B virus infection was the most common etiology (59.1%). The rates of Barcelona Clinic Liver Cancer (BCLC) stages 0, A, B, C, and D at diagnosis were 3.9%, 36.9%, 12.5%, 39.4%, and 7.3%, respectively. The proportion of very early or early stage HCC at diagnosis (BCLC stage 0 or A) in the 2012-2014 cohort was significantly lower than that in the 2008-2011 cohort (40.8% vs. 48.3%, P<0.001). Transarterial therapy (37.5%) was the most commonly performed initial treatment, followed by surgical resection (19.8%), best supportive care (19.1%), and local ablation (10.6%). The median OS was 2.9 years, and the 1-, 3-, and 5-year OS rates were 67.7%, 49.3% and 41.9%, respectively. The OS rate of the 2012-2014 cohort was significantly higher than that of the 2008-2011 cohort (log-rank, P<0.001).Conclusions: The OS of HCC patients registered in the KPLCR between 2012 and 2014 significantly improved. Nevertheless, as about half of the HCC patients were diagnosed at an advanced stage, vigorous and optimized HCC screening strategies should be implemented.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"20 2","pages":"135-147"},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fa/4d/jlc-20-2-135.PMC10035678.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9734952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic Significance of Preoperative Controlling Nutritional Status Score in Patients Who Underwent Hepatic Resection for Hepatocellular Carcinoma. 肝癌肝切除术患者术前控制营养状况评分的预后意义。

Journal of Liver Cancer Pub Date : 2020-09-01 DOI: 10.17998/jlc.20.2.106

Bum-Soo Kim

引用次数: 0

Is Transarterial Chemoembolization Only Treatment Option in Patients with Intermediate Stage of Hepatocellular Carcinoma?: in Perspectives of Surgery. 经动脉化疗栓塞是中期肝细胞癌患者唯一的治疗选择吗?:《外科透视》。

Journal of Liver Cancer Pub Date : 2020-09-01 DOI: 10.17998/jlc.20.2.113

Ji Young Lim, Minjong Lee, Tae Hun Kim

引用次数: 0

Huge Hepatocellular Carcinoma Exhibiting a Complete Response after Stereotactic Body Radiation Therapy. 立体定向全身放射治疗后显示完全缓解的巨大肝癌。

Journal of Liver Cancer Pub Date : 2020-09-01 DOI: 10.17998/jlc.20.2.167

Kyung In Shin, Byoung Kuk Jang, Jin Hee Kim, Jae Seok Hwang

{"title":"Huge Hepatocellular Carcinoma Exhibiting a Complete Response after Stereotactic Body Radiation Therapy.","authors":"Kyung In Shin, Byoung Kuk Jang, Jin Hee Kim, Jae Seok Hwang","doi":"10.17998/jlc.20.2.167","DOIUrl":"https://doi.org/10.17998/jlc.20.2.167","url":null,"abstract":"To date, there are limited data and little consensus on treatment strategies for huge hepatocellular carcinoma (HCC). Surgical resection provides significantly better survival than other modalities for single large HCC regardless of tumor stage. Recently, with technological advances in radiation therapy, stereotactic body radiation therapy (SBRT) is considered an alternative treatment option for HCC. Herein, we present a case of huge HCC that was successfully managed by SBRT. Transarterial embolization, previously performed in Russia, was incomplete. It was also not suitable for resection and transarterial chemoembolization. Although the rationale for radiotherapy in huge HCC was insufficient, SBRT was performed because no other treatment options were available. Additional radiofrequency ablation was performed for small HCC in a different segment, and radiological complete response (CR) was achieved. The CR was maintained over 4 years. Therefore, SBRT may be an alternative treatment option for large HCC that is not suitable for curative treatment.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"20 2","pages":"167-172"},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bb/79/jlc-20-2-167.PMC10035669.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9734949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0